This study will evaluate the implementation of a PrEP program for youth aged 13-24 in Phoenix, AZ. Numbers of youth who initiate PrEP, how long they continue with PrEP, and the barriers for youth who are trying to initiate and continue taking PrEP will be examined.

This observational study will describe the barriers encountered and the benefits found as youth engage in a PrEP program, the Phoenix PrEP Access Project and as they participate in PrEP provided through standard medical care. This study does not investigate the safety, efficacy or other medical benefits of PrEP, but looks at the issues surrounding youth who are trying to access PrEP.

Inclusion Criteria

• sexually active youth aged 13 through 24,
• at risk for contracting HIV,
• Negative for HIV as indicated by Negative Elisa and Western Blot (WB) or Negative 4th Generation test,
• weight greater than 35kg,
• offered PrEP to reduce the risk of contracting HIV.

Exclusion Criteria

• Unknown or Positive HIV status,
• Renal Impairment as indicated by elevated BUN or Creatinine, abnormal urinalysis,
• Active infection with Hepatitis B Virus,
• Taking other medications containing Emtricitabine, Tenofovir or tenofovir alafenamide(TAF) such as Atripla, Complera, Emtriva, Genvoya, Odefsey, Stribild, and Viread taking drugs containing lamivudine,
• taking Hepsera,
• clinical symptoms consistent with acute viral infection within the past month.

Youth aged 13 through 24 in the Phoenix area who are high risk for HIV infections because of unsafe sex practices and or IV drug use and have been offered PrEP as part of their standard medical care.